NCT00263068View on ClinicalTrials.gov

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Restless Legs Syndrome
Interventions
DRUG

Rotigotine

"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"

Trial Locations (1)

Unknown

Schwarz, RTP

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00263068 - An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome | Biotech Hunter | Biotech Hunter